middle.news
Neurizon’s NUZ-001 Extends ALS Patient Survival by Over 11 Months in OLE Study
9:23am on Monday 5th of May, 2025 AEST
•
Biotechnology
Read Story
Neurizon’s NUZ-001 Extends ALS Patient Survival by Over 11 Months in OLE Study
9:23am on Monday 5th of May, 2025 AEST
Key Points
Last patient completes 12-month treatment in NUZ-001 OLE study
NUZ-001 reduces risk of death by 78.5% compared to historical controls
Median survival extended by approximately 11 months
No serious adverse events related to NUZ-001 reported
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE